Among them, TET2 is unique in that it distinctly exhibits high mutation ratios in myeloid malignancies (Extended Data Fig. 1a), with frequent IDH mutations observed in human cancers also thought to mainly act through TET2 inhibition9–11. The gene discussed is TET2; the disease is cancer.